US Stocks Movement: Revolution Medicines surges on October 20th — Phase III trial launch and RAS-targeted drug

Revolution Medicines Surges on October 20: Analysis

Keywords: Phase III trial launch, RAS-targeted drug

1. On October 20, the company announced the launch of the global Phase III RASolve 308 trial and the commencement of patient treatment to evaluate zoldonrasib in combination with pembrolizumab and chemotherapy as a first-line treatment for metastatic RAS G12D non-squamous non-small cell lung cancer.

2. The company stated that this patient population accounts for approximately 4% of non-small cell lung cancer cases and that there are currently no approved targeted therapies; previous preliminary clinical data from the combination therapy demonstrated anti-tumor activity and safety characteristics, providing a clinical basis for starting the Phase III trial.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)